Table 4.

Inhibitory activity against WT HIV-1 RT of target compounds 11–32.

Compd.	IC50 (μmol/L)a	Compd.	IC50 (μmol/L)a
11	0.243 ± 0.037	22	0.233 ± 0.028
12	0.901 ± 0.045	23	0.211 ± 0.015
13	0.265 ± 0.059	24	0.171 ± 0.010
14	0.249 ± 0.001	25	0.288 ± 0.026
15	0.227 ± 0.046	26	0.182 ± 0.016
16	0.595 ± 0.044	27	0.207 ± 0.006
17	0.167 ± 0.014	28	0.202 ± 0.020
18	0.624 ± 0.055	29	0.477 ± 0.009
19	0.164 ± 0.005	30	0.473 ± 0.059
20	0.161 ± 0.014	31	1.681 ± 0.056
21	0.268 ± 0.052	32	0.271 ± 0.016
NVP	1.220 ± 0.337	ETRb	0.011 ± 0.000
EFVb	0.030 ± 0.000	K-5a2b	0.300 ± 0.060

^aIC₅₀: inhibitory concentration of test compound required to inhibit biotin deoxyuridine triphosphate (biotindUTP) incorporation into WT HIV-1 RT by 50%.

^bThe data were obtained from the same laboratory with the same method (Prof. Erik De Clercq, Rega Institute for Medical Research, KU Leuven, Belgium).